Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
A new U.S. law could push big pharma companies toward more diverse drug pipelines and away from an era of high-priced and complex medicines. → Read More
Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid. → Read More
This year will bring news on mRNA flu vaccines and the jabs for RSV and Covid-19 from companies like Pfizer, Moderna, and GSK. → Read More
CVS Health staked its future on primary care, but a year later it still hasn't made an acquisition. Should investors be worried? → Read More
CVS Health staked its future on primary care, but a year later it still hasn't made an acquisition. Should investors be worried? → Read More
The company’s last attempt to target the devastating disease flopped. Results from a key trial of Biogen and Eisai’s new drug, lecanemab, are coming soon—and have huge implications. → Read More
The decision to give the treatment a second hearing may be a positive sign for the drug's eventual approval. → Read More
Children under 5 years old are on their way to being able to be vaccinated. → Read More
The executive who replaces Michel Vounatsos will inherit a large-cap biotech facing significant challenges. → Read More
The virus can change quickly, and another Omicron-like wave is possible. How to think about the evolution of Covid over the next two years. → Read More
As Dr. Robert Califf takes the reins, investors will be watching for what the agency does on ALS and Alzheimer’s drugs, Covid vaccines, and others. → Read More
It's the big pharma company that "has the best stuff with the least warts,” says T. Rowe Price’s Ziad Bakri. → Read More
The beleaguered sector is showing no real signs of recovery. That could spell an opportunity for some stocks. → Read More
The firm expects record revenue in 2022 and sees a big increase in sales of its Covid antiviral. Total revenue projections fell short of expectations. → Read More
A pullback, even if largely symbolic, could give a boost to economic activity. → Read More
Drug companies and regulators are making adjustments to cope with the challenges posed by the Covid-19 variant. → Read More
Omicron wave shows how two years of pandemic has weakened the healthcare workforce in the U.S. → Read More
A broader push could shore up the stocks of the vaccine makers. → Read More
Successes with its Covid-19 vaccine and antiviral pill appear to validate a strategic shift by the drugmaker. → Read More
Successes with its Covid-19 vaccine and antiviral pill appear to validate a strategic shift by the drugmaker. → Read More